Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 17Abaloparatide (Tymlos) literatureBioactive materials · Animal study · Preclinical2026

Restoring cartilage-subchondral bone metabolism with biphasic magnesium microspheres ameliorate early osteoarthritis.

Magnesium-releasing microspheres may halt early osteoarthritis progression if administered promptly, highlighting the importance of early intervention.

Read at Bioactive materialsAdd to compare

Where it sits

this study against the rest of the abaloparatide (tymlos) corpus
6
Preclinical · this one
4
Observational
0
Open-label
0
Randomised
7
Reviews

Summary and findings

The study investigated the effects of magnesium-releasing biphasic microspheres on early osteoarthritis progression in a murine model. Early administration halted disease progression, while delayed treatment primarily benefited subchondral bone. The findings highlight a critical window for intervention in osteoarthritis using magnesium-based biomaterials.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Preclinical2026

Abstract

The authors’ words, as Bioactive materials supplied them

The spatiotemporal histopathological features of articular cartilage in osteoarthritis (OA) remain inadequately characterized, which impedes the advancement of strategies to halt irreversible joint deterioration. Herein a murine OA model, the initial phase (<10 days post-surgery) is characterized by pronounced mitochondrial dysfunction in chondrocytes and concurrent activation of subchondral osteoclasts. Beyond this period, irreversible cartilage degeneration ensues, marked by chondrocyte apoptosis and subchondral bone sclerosis. We further identified magnesium (Mg) as a key regulator of cellular metabolic balance, capable of reinstating homeostasis in inflamed chondrocytes while modulating osteoclast overactivity. Based on this, we developed dual-concentration Mg-releasing biphasic microspheres that effectively halted early OA progression in vivo. In contrast, delayed administration conferred benefits predominantly limited to the subchondral bone, without achieving cartilage preservation. These results underscore the existence of a critical therapeutic window for metabolic intervention in OA, wherein Mg-based biomaterials exert protective effects exclusively during the early disease stage. Thus, this study offers a new strategic perspective for the clinical management of OA.

Background

Osteoarthritis (OA) is characterized by joint deterioration, with articular cartilage and subchondral bone changes playing critical roles. Current understanding of the disease's spatiotemporal progression is limited, hindering effective intervention strategies. This study addresses the need for targeted metabolic interventions in the early stages of OA to prevent irreversible damage.

Methods

The study utilized a murine model of osteoarthritis to examine the effects of magnesium on cartilage and subchondral bone metabolism. The researchers developed biphasic magnesium-releasing microspheres and administered them at different stages of OA progression. The primary outcomes included mitochondrial function in chondrocytes and osteoclast activity in subchondral bone.

Results

In the initial phase of OA (<10 days post-surgery), there was pronounced mitochondrial dysfunction in chondrocytes and activation of subchondral osteoclasts. Magnesium was found to restore metabolic balance in inflamed chondrocytes and modulate osteoclast activity. Early administration of magnesium-releasing microspheres halted OA progression, while delayed treatment primarily benefited subchondral bone without preserving cartilage.

Interpretation

The study suggests that magnesium-based interventions may be effective in halting early OA progression by targeting metabolic dysfunctions. However, the findings are limited to a murine model and may not directly translate to human OA. The critical therapeutic window identified implies that timing is crucial for the efficacy of such interventions.

Key findings

  • Pronounced mitochondrial dysfunction in chondrocytes <10 days post-surgery.
  • Irreversible cartilage degeneration marked by chondrocyte apoptosis and subchondral bone sclerosis.
  • Magnesium reinstated homeostasis in inflamed chondrocytes.
  • Dual-concentration Mg microspheres halted early OA progression in vivo.
  • Delayed administration benefited subchondral bone but not cartilage.

Limitations

  • murine model, not human
  • early disease stage only
  • no long-term follow-up
  • potential species-specific effects

Elsewhere in the Abaloparatide (Tymlos) corpus

CDMP1-Cre expressing cells mediate the gain in bone mass and strength, but not the increase in bone remodeling, induced by ligands of the parathyroid hormone receptor.Bone research · 2026 · PTH/ABL increased bone mass and strength only in fl/fl littermates.AnimalCParathyroid Hormone Modulates Alveolar Bone Metabolism via Inducing Periodontal Ligament Stem Cells Aerobic Glycolysis.International dental journal · 2026 · Not reported in abstract.AnimalCOxygen‑sensing histone demethylase KDM6A modulates chondrocyte‑to‑osteoblast transdifferentiation by activating the Wnt/β‑catenin pathway.International journal of molecular medicine · 2026 · Not reported in abstract.AnimalCTFF1-mediated suppression of the TCA cycle promotes bone metastasis in triple-negative breast cancer.Translational oncology · 2026 · Deletion of TFF1 reduced metastatic burden and extended survival in mouse models.AnimalDSpatiotemporal complexity and druggability of PTH1R: insights from small molecules and peptides.Molecular and cellular endocrinology · 2026reviewDCallus geometry as a reflection of fracture healing biology and a candidate imaging biomarker: A systematic review of biological, mechanical, and clinical evidence.Bone · 2026 · Not reported in abstract.review